139 related articles for article (PubMed ID: 32251585)
1. Design, Synthesis, and Characterization of the Macrocyclic Tetrapeptide
Ferracane MJ; Brice-Tutt AC; Coleman JS; Simpson GG; Wilson LL; Eans SO; Stacy HM; Murray TF; McLaughlin JP; Aldrich JV
ACS Chem Neurosci; 2020 May; 11(9):1324-1336. PubMed ID: 32251585
[TBL] [Abstract][Full Text] [Related]
2. Multifunctional opioid receptor agonism and antagonism by a novel macrocyclic tetrapeptide prevents reinstatement of morphine-seeking behaviour.
Brice-Tutt AC; Wilson LL; Eans SO; Stacy HM; Simons CA; Simpson GG; Coleman JS; Ferracane MJ; Aldrich JV; McLaughlin JP
Br J Pharmacol; 2020 Sep; 177(18):4209-4222. PubMed ID: 32562259
[TBL] [Abstract][Full Text] [Related]
3. Phenylalanine Stereoisomers of CJ-15,208 and [d-Trp]CJ-15,208 Exhibit Distinctly Different Opioid Activity Profiles.
Brice-Tutt AC; Senadheera SN; Ganno ML; Eans SO; Khaliq T; Murray TF; McLaughlin JP; Aldrich JV
Molecules; 2020 Sep; 25(17):. PubMed ID: 32887303
[TBL] [Abstract][Full Text] [Related]
4. Alanine analogues of [D-Trp]CJ-15,208: novel opioid activity profiles and prevention of drug- and stress-induced reinstatement of cocaine-seeking behaviour.
Aldrich JV; Senadheera SN; Ross NC; Reilley KA; Ganno ML; Eans SE; Murray TF; McLaughlin JP
Br J Pharmacol; 2014 Jul; 171(13):3212-22. PubMed ID: 24588614
[TBL] [Abstract][Full Text] [Related]
5. Novel opioid cyclic tetrapeptides: Trp isomers of CJ-15,208 exhibit distinct opioid receptor agonism and short-acting κ opioid receptor antagonism.
Ross NC; Reilley KJ; Murray TF; Aldrich JV; McLaughlin JP
Br J Pharmacol; 2012 Feb; 165(4b):1097-108. PubMed ID: 21671905
[TBL] [Abstract][Full Text] [Related]
6. Tryptophan Substitution in CJ-15,208 (
Scherrer KH; Eans SO; Medina JM; Senadheera SN; Khaliq T; Murray TF; McLaughlin JP; Aldrich JV
Pharmaceuticals (Basel); 2023 Aug; 16(9):. PubMed ID: 37765026
[TBL] [Abstract][Full Text] [Related]
7. The macrocyclic tetrapeptide [D-Trp]CJ-15,208 produces short-acting κ opioid receptor antagonism in the CNS after oral administration.
Eans SO; Ganno ML; Reilley KJ; Patkar KA; Senadheera SN; Aldrich JV; McLaughlin JP
Br J Pharmacol; 2013 May; 169(2):426-36. PubMed ID: 23425081
[TBL] [Abstract][Full Text] [Related]
8. An analog of [d-Trp]CJ-15,208 exhibits kappa opioid receptor antagonism following oral administration and prevents stress-induced reinstatement of extinguished morphine conditioned place preference.
Brice-Tutt AC; Eans SO; Yakovlev D; Aldrich JV; McLaughlin JP
Pharmacol Biochem Behav; 2022 Jun; 217():173405. PubMed ID: 35584724
[TBL] [Abstract][Full Text] [Related]
9. The macrocyclic peptide natural product CJ-15,208 is orally active and prevents reinstatement of extinguished cocaine-seeking behavior.
Aldrich JV; Senadheera SN; Ross NC; Ganno ML; Eans SO; McLaughlin JP
J Nat Prod; 2013 Mar; 76(3):433-8. PubMed ID: 23327691
[TBL] [Abstract][Full Text] [Related]
10. Peptide Kappa Opioid Receptor Ligands and Their Potential for Drug Development.
Aldrich JV; McLaughlin JP
Handb Exp Pharmacol; 2022; 271():197-220. PubMed ID: 34463847
[TBL] [Abstract][Full Text] [Related]
11. Development of a robust, sensitive and selective liquid chromatography-tandem mass spectrometry assay for the quantification of the novel macrocyclic peptide kappa opioid receptor antagonist [D-Trp]CJ-15,208 in plasma and application to an initial pharmacokinetic study.
Khaliq T; Williams TD; Senadheera SN; Aldrich JV
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Aug; 1028():11-15. PubMed ID: 27318293
[TBL] [Abstract][Full Text] [Related]
12. Involvement of spinal release of α-neo-endorphin on the antinociceptive effect of TAPA.
Mizoguchi H; Kon-No T; Watanabe H; Watanabe C; Yonezawa A; Sato T; Sakurada T; Sakurada S
Peptides; 2013 Dec; 50():139-44. PubMed ID: 24126280
[TBL] [Abstract][Full Text] [Related]
13. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
[TBL] [Abstract][Full Text] [Related]
14. In vivo antinociception of potent mu opioid agonist tetrapeptide analogues and comparison with a compact opioid agonist-neurokinin 1 receptor antagonist chimera.
Guillemyn K; Kleczkowska P; Novoa A; Vandormael B; Van den Eynde I; Kosson P; Asim MF; Schiller PW; Spetea M; Lipkowski AW; Tourwé D; Ballet S
Mol Brain; 2012 Jan; 5():4. PubMed ID: 22289619
[TBL] [Abstract][Full Text] [Related]
15. N-cyclobutylmethyl analog of normorphinone, N-CBM-TAMO: a short-term opioid agonist and long-term Mu-selective irreversible opioid antagonist.
Xu JY; Seyed-Mozaffari A; Archer S; Bidlack JM
J Pharmacol Exp Ther; 1996 Nov; 279(2):539-47. PubMed ID: 8930155
[TBL] [Abstract][Full Text] [Related]
16. Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opioid receptor antagonist pharmacophores.
Lenard NR; Daniels DJ; Portoghese PS; Roerig SC
Eur J Pharmacol; 2007 Jul; 566(1-3):75-82. PubMed ID: 17383633
[TBL] [Abstract][Full Text] [Related]
17. Zyklophin, a systemically active selective kappa opioid receptor peptide antagonist with short duration of action.
Aldrich JV; Patkar KA; McLaughlin JP
Proc Natl Acad Sci U S A; 2009 Oct; 106(43):18396-401. PubMed ID: 19841255
[TBL] [Abstract][Full Text] [Related]
18. Versatile Picklocks To Access All Opioid Receptors: Tuning the Selectivity and Functional Profile of the Cyclotetrapeptide c[Phe-d-Pro-Phe-Trp] (CJ-15,208).
De Marco R; Bedini A; Spampinato S; Cavina L; Pirazzoli E; Gentilucci L
J Med Chem; 2016 Oct; 59(19):9255-9261. PubMed ID: 27607020
[TBL] [Abstract][Full Text] [Related]
19. Effects of naloxone and D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 and the protein kinase inhibitors H7 and H8 on acute morphine dependence and antinociceptive tolerance in mice.
Bilsky EJ; Bernstein RN; Wang Z; Sadée W; Porreca F
J Pharmacol Exp Ther; 1996 Apr; 277(1):484-90. PubMed ID: 8613958
[TBL] [Abstract][Full Text] [Related]
20. The behavioral effects of a mixed efficacy antinociceptive peptide, VRP26, following chronic administration in mice.
Anand JP; Boyer BT; Mosberg HI; Jutkiewicz EM
Psychopharmacology (Berl); 2016 Jul; 233(13):2479-87. PubMed ID: 27117141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
